148 related articles for article (PubMed ID: 15509692)
1. Miniature tissue microarrays for HercepTest standardisation and analysis.
Gulmann C; Loring P; O'Grady A; Kay E
J Clin Pathol; 2004 Nov; 57(11):1229-31. PubMed ID: 15509692
[TBL] [Abstract][Full Text] [Related]
2. Tissue microarray technology in the routine assessment of HER-2 status in invasive breast cancer: a prospective study of the use of immunohistochemistry and fluorescence in situ hybridization.
Graham AD; Faratian D; Rae F; Thomas JS
Histopathology; 2008 Jun; 52(7):847-55. PubMed ID: 18494613
[TBL] [Abstract][Full Text] [Related]
3. Tissue microarray for routine analysis of breast biomarkers in the clinical laboratory.
Thomson TA; Zhou C; Chu C; Knight B
Am J Clin Pathol; 2009 Dec; 132(6):899-905. PubMed ID: 19926582
[TBL] [Abstract][Full Text] [Related]
4. Rapid screening of tissue microarrays for Her-2 fluorescence in situ hybridization testing is an accurate, efficient and economic method of providing an entirely in situ hybridization-based Her-2 testing service.
Faratian D; Graham A; Rae F; Thomas J
Histopathology; 2009 Mar; 54(4):428-32. PubMed ID: 19309394
[TBL] [Abstract][Full Text] [Related]
5. c-erbB-2 (HER-2/neu) immunohistochemistry in invasive breast cancer: is there concordance between standard sections and tissue microarrays?
Selvarajan S; Tan SY; Sii LH; Tan PH
Pathology; 2006 Aug; 38(4):316-20. PubMed ID: 16916720
[TBL] [Abstract][Full Text] [Related]
6. Validation of tissue microarray technology in vulvar cancer.
Fons G; van der Velden J; Burger M; ten Kate F
Int J Gynecol Pathol; 2009 Jan; 28(1):76-82. PubMed ID: 19047904
[TBL] [Abstract][Full Text] [Related]
7. Use of tissue microarray for interlaboratory validation of HER2 immunocytochemical and FISH testing.
Kay E; O'Grady A; Morgan JM; Wozniak S; Jasani B
J Clin Pathol; 2004 Nov; 57(11):1140-4. PubMed ID: 15509672
[TBL] [Abstract][Full Text] [Related]
8. Validation of tissue microarray technology in malignant peripheral nerve sheath tumours.
Cunha KS; Caruso AC; Gonçalves AS; Bernardo VG; Pires AR; da Fonseca EC; de Faria PA; da Silva LE; Geller M; de Moura-Neto RS; Lopes VS
J Clin Pathol; 2009 Jul; 62(7):629-33. PubMed ID: 19318344
[TBL] [Abstract][Full Text] [Related]
9. Tissue microarrays compared with whole sections and biochemical analyses. A subgroup analysis of DBCG 82 b&c.
Kyndi M; Sørensen FB; Knudsen H; Overgaard M; Nielsen HM; Andersen J; Overgaard J
Acta Oncol; 2008; 47(4):591-9. PubMed ID: 18465327
[TBL] [Abstract][Full Text] [Related]
10. Tissue microarray validation: a methodologic study with special reference to lung cancer.
Karlsson C; Bodin L; Piehl-Aulin K; Karlsson MG
Cancer Epidemiol Biomarkers Prev; 2009 Jul; 18(7):2014-21. PubMed ID: 19531681
[TBL] [Abstract][Full Text] [Related]
11. Tissue microarrays for routine diagnostic assessment of HER2 status in breast carcinoma.
Drev P; Grazio SF; Bracko M
Appl Immunohistochem Mol Morphol; 2008 Mar; 16(2):179-84. PubMed ID: 18227723
[TBL] [Abstract][Full Text] [Related]
12. iCon-TMA for control and quantitation of immunohistochemistry and in situ molecular pathology analysis.
Petersen I; Blind C; Koepenik A; Dietel M; Krenn V
Pathol Res Pract; 2007; 203(8):629-31. PubMed ID: 17590280
[TBL] [Abstract][Full Text] [Related]
13. Robust gridding of TMAs after whole-slide imaging using template matching.
Lahrmann B; Halama N; Westphal K; Ernst C; Elsawaf Z; Sinn P; Bosch FX; Dickhaus H; Jäger D; Schirmacher P; Grabe N
Cytometry A; 2010 Dec; 77(12):1169-76. PubMed ID: 20662092
[TBL] [Abstract][Full Text] [Related]
14. HER-2/neu gene amplification in ovarian tumours: a comprehensive immunohistochemical and FISH analysis on tissue microarrays.
Mayr D; Kanitz V; Amann G; Engel J; Burges A; Löhrs U; Diebold J
Histopathology; 2006 Jan; 48(2):149-56. PubMed ID: 16405663
[TBL] [Abstract][Full Text] [Related]
15. Construction of tissue microarrays using pre-existing slides as source of tissue when paraffin blocks are unavailable.
Deng FM; Zhao Y; Kong X; Lee P; Melamed J
J Clin Pathol; 2013 Jul; 66(7):627-9. PubMed ID: 23476078
[TBL] [Abstract][Full Text] [Related]
16. Tissue microarrays from renal cell tumors: exclusion criteria and rate of exclusion.
Hager M; Kolbitsch C; Tiefenthaler W; Haufe H; Kemmerling R; Lucia Moser P
Scand J Urol Nephrol; 2007; 41(6):485-9. PubMed ID: 17853046
[TBL] [Abstract][Full Text] [Related]
17. Quantitative justification of the change from 10% to 30% for human epidermal growth factor receptor 2 scoring in the American Society of Clinical Oncology/College of American Pathologists guidelines: tumor heterogeneity in breast cancer and its implications for tissue microarray based assessment of outcome.
Moeder CB; Giltnane JM; Harigopal M; Molinaro A; Robinson A; Gelmon K; Huntsman D; Camp RL; Rimm DL; ;
J Clin Oncol; 2007 Dec; 25(34):5418-25. PubMed ID: 18048824
[TBL] [Abstract][Full Text] [Related]
18. HER-2/neu analysis in breast cancer bone metastases.
Zustin J; Boddin K; Tsourlakis MC; Burandt E; Mirlacher M; Jaenicke F; Izbicki J; Ruether W; Rueger JM; Bokemeyer C; Simon R; Sauter G
J Clin Pathol; 2009 Jun; 62(6):542-6. PubMed ID: 19474354
[TBL] [Abstract][Full Text] [Related]
19. Application of novel tissue microarrays to investigate expression of tryptase, chymase and KIT protein in placental mast cells.
Noack F; Krüger S; Thorns C; Finas D; Stöcker W; Diedrich K; Horny HP
Arch Gynecol Obstet; 2005 Sep; 272(3):223-8. PubMed ID: 16142475
[TBL] [Abstract][Full Text] [Related]
20. A new approach to the validation of tissue microarrays.
Goethals L; Perneel C; Debucquoy A; De Schutter H; Borghys D; Ectors N; Geboes K; McBride WH; Haustermans KM
J Pathol; 2006 Apr; 208(5):607-14. PubMed ID: 16435284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
